Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Angiotensin-(1-7) in Peripheral Arterial Disease
NCT03240068Phase 1Terminated
- Sponsor
- Penn State Health Milton S. Hershey Medical Center
- Start
- Sep 2017
- Primary completion
- Mar 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of angiotensin-(1-7) in Peripheral Arterial Disease (PAD) (2 arms), sponsored by Penn State Health Milton S. Hershey Medical Center. Primary endpoints: Leg Blood Flow at 50 minutes and Inflammatory Markers at 50 minutes. Started Sep 2017; status: terminated.
02
Drugs
angiotensin-(1-7)
03
Conditions
Peripheral Arterial Disease (PAD)
Beyond the preview
Go deeper on NCT03240068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03240068.